Nomad Foods to Report Second Quarter 2022 Results on Wednesday, August 10, 2022
Get Alerts NOMD Hot Sheet
Overall Analyst Rating:
BUY (= Flat)
Dividend Yield: 3.5%
Revenue Growth %: +2.9%
Join SI Premium – FREE
FELTHAM, England, July 27, 2022 /PRNewswire/ -- Nomad Foods Limited (NYSE: NOMD) today announced it will report results for the second quarter ended June 30, 2022 before New York Stock Exchange market open on Wednesday, August 10, 2022. A conference call with members of the executive management team will be held to discuss the results with additional comments and details.
The conference call is scheduled to begin at 8:30 AM Eastern Daylight Time on Wednesday, August 10, 2022. To participate on the live call listeners in North America may dial +1-877-300-8521 and international listeners may dial +1-412-317-6026. Additionally, there will be a presentation to accompany the conference call and the call is being webcast. Both can be accessed at the Nomad Foods website at www.nomadfoods.com under Investor Relations. A replay of the conference call will be available on the Company website for two weeks following the event and can be accessed by listeners in North America by dialing +1-844-512-2921 and by international listeners by dialing +1-412-317-6671; the replay pin number is 10169497.
About Nomad Foods
Nomad Foods (NYSE: NOMD) is Europe's leading frozen food company. The company's portfolio of iconic brands, which includes Birds Eye, Findus, iglo, Ledo and Frikom, have been a part of consumers' meals for generations, standing for great tasting food that is convenient, high quality and nutritious. Nomad Foods is headquartered in the United Kingdom. Additional information may be found at www.nomadfoods.com.
Nomad Foods ContactsInvestor Relations ContactAnthony BucaloNomad Foods Limited+1-914-907-8724
View original content:https://www.prnewswire.com/news-releases/nomad-foods-to-report-second-quarter-2022-results-on-wednesday-august-10-2022-301593619.html
SOURCE Nomad Foods Limited
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vortex Metal Announces Upsized $1.75 Million Non Brokered Private Placement
- GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
- Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!